ABP 310
Alternative Names: ABP-310Latest Information Update: 22 Dec 2021
At a glance
- Originator Abpro Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 09 Dec 2021 Preclinical trials in COVID-2019 infections in USA (Parenteral)
- 09 Dec 2021 Abpro Therapeutics plans to seek emergency use authorisation approval for ABP 310 in COVID 2019 infections as early as 2022
- 09 Dec 2021 Pharmacodynamics data from a preclinical study in COVID 2019 infections released by Abpro Therapeutics